Fibrinolytics: from the thrombolysis to the processes of blood vessels growth and remodeling, neurogenesis, carcinogenesis and fibrosis


Cite item

Full Text

Abstract

One of the most outstanding scientific achievements in the thrombolysis is the development and administration of fibrinolysin - the first Soviet drug that lyses blood clots. Intracoronary administration of fibrinolysin reduced the mortality of patients with myocardial infarction by almost 20%. For his work in this field Yevgeny Chazov was awarded the Lenin Prize in 1982. Over the next decades, under his leadership, the Cardiology Center established scientific and clinical laboratories that created new generations of drugs based on fibrinolytics for treating patients with myocardial infarction, restoration of blood flow in ischemic tissue, and also studying the mechanisms of remodeling of blood vessels involving the fibrinolysis system. It have been found new mechanisms of regulation of the navigation of blood vessels and nerves growth, tumor growth and its metastasis with the participation of the fibrinolysis system proteins. The review reports the role of the fibrinolysis system in the thrombolysis, blood vessels growth and remodeling, neurogenesis, carcinogenesis and fibrosis. The article is dedicated to the 90th anniversary of academician E.I. Chazov.

About the authors

V A Tkachuk

National Medical Research Center of Cardiology

акад., руководитель лаб. молекулярной эндокринологии НИИЭК ФГБУ «НМИЦ кардиологии» Минздрава России, ORCID: 0000-0002-7492-747X Moscow, Russia

Ye V Parfyonova

National Medical Research Center of Cardiology

проф., директор НИИЭК ФГБУ «НМИЦ кардиологии» Минздрава России, ORCID: 0000-0002-0969-5780 Moscow, Russia

O S Plekhanova

National Medical Research Center of Cardiology

д.м.н., в.н.с. лаб. молекулярной эндокринологии НИИЭК ФГБУ «НМИЦ кардиологии» Минздрава России, ORCID: 0000-0002-4693-295X Moscow, Russia

V V Stepanova

National Medical Research Center of Cardiology

к.б.н., Research associate professor, Pathology and laboratory medicine Perelman School of Medicine, University of Pennsylvania, PA, USA, ORCID: 0000-0002-9313-5742 Moscow, Russia

M Yu Menshikov

National Medical Research Center of Cardiology

д.м.н., в.н.с. лаб. ангиогенеза НИИЭК ФГБУ «НМИЦ кардиологии» Минздрава России, ORCID: 0000-0002-3348-297X Moscow, Russia

E V Semina

National Medical Research Center of Cardiology

Email: e-semina@yandex.ru
к.б.н., в.н.с. лаб. молекулярной эндокринологии НИИЭК ФГБУ «НМИЦ кардиологии» Минздрава России, ORCID: 0000-0002-3927-9286 Moscow, Russia

R Sh Bibilashvili

National Medical Research Center of Cardiology

к.ф.-м.н., руководитель лаб. генной инженерии НИИЭК ФГБУ «НМИЦ кардиологии» Минздрава России Moscow, Russia

E I Chazov

National Medical Research Center of Cardiology

акад., почетный директор ФГБУ «НМИЦ кардиологии» Минздрава России Moscow, Russia

References

  1. Чазов Е.И. О прижизненном разрушении экспериментального тромбоза в коронарных сосудах. Бюллетень экспериментальной биологии и медицины. 1961;8:22-5.
  2. Чазов Е.И., Андреенко Г.В. Первый опыт терапии тромбоза отечественным фибринолизином. Кардиология. 1962;4:59-64.
  3. Чазов Е.И., Матвеева Л.С., Мазаев А.В., Саргин К.Е., Садовская Г.В., Руда М.Я. Внутрикоронарное назначение фибринолизина при остром инфаркте миокарда. Терапевтический архив. 1976;48(4):8-19.
  4. Патент СССР на изобретение №1692151. Бюллетень №13. Белогуров А.А., Бибилашвили Р.Ш., Горюнова Л.Е., Дельвер Е.П., Домкин В.Д., Ефимова Е.П., Рыбалкин И.Н., Савочкина Л.П., Сидоров М.А., Скамров А.В., Ченчик А.А., Шевелев А.Я., Южаков А.А. Рекомбинантная плазмидная ДНК рuавс, кодирующая активатор плазминогена урокиназного типа, способ ее конструирования и штамм бактерий escherichia coli продуцент активатора плазминогена урокиназного типа. Ссылка активна на 07.07.2019 http://patents.su/1-1692151-rekombinantnaya-plazmidnaya-dnk-ruavs-kodiruyushhaya-aktivator-plazminogena-urokinaznogo-tipa-sposob-ee-konstruirovaniya-i-shtamm-bakterijj-escherichia-coli-producent-aktivatora-pl.html.
  5. Чазов Е.И. Роль достижений фундаментальной науки в повышении эффективности лечения. Терапевтический архив. 2005;77(8):5-9.
  6. Nicholl S.M, Roztocil E, Davies M.G. Plasminogen activator system and vascular disease. Curr Vasc Pharmacol. 2006;4:101-16. doi: 10.2174/ 157016106776359880
  7. Blasi F. The urokinase receptor: a cell surface, regulated chemokine. APMIS. 1999;107:96-101. doi: https://doi.org/10.1111/j.1699-0463.1999. tb01531.x
  8. Tkachuk V.A, Plekhanova O.S, Parfyonova Y.V. Regulation of arterial remodeling and angiogenesis by urokinase - type plasminogen activator. Can J Physiol Pharmacol. 2009;87(4):231-51. doi: 10.1139/Y08-113
  9. Cui K, Lyu S, Song X, Yuan F, Xu F, Zhang M, Wang W, Zhang D, Dai J. Drug - eluting balloon versus bare - mental stent and drug - eluting stent for de novo coronary artery disease: A systematic review and meta - analysis of 14 randomized controlled trials. PLoS One. 2017;12(4):e0176365. doi: 10.1371/journal.pone.0176365. eCollection 2017
  10. Araújo P.V, Ribeiro M.S, Dalio M.B, Rocha L.A, Viaro F, Dellalibera Joviliano R, Piccinato C.E, Évora P.R, Joviliano E.E. Interleukins and inflammatory markers in in - stent restenosis after femoral percutaneous transluminal angioplasty. Ann Vasc Surg. 2015;29(4):731-7. doi: 10.1016/ j.avsg.2014.12.006
  11. Plekhanova O, Parfyonova Ye, Bibilashvily R, Domogatskii S, Stepanova V, Gulba D.C, Agrotis A, Bobik A, Tkachuk V. Urokinase plasminogen activator augments cell proliferation and neointima formation in injured arteries via proteolytic mechanisms. Atherosclerosis. 2001;159(2):297-306. doi: https://doi.org/10.1016/S0021-9150(01)00511-1
  12. Plekhanova O, Parfyonova Ye, Bibilashvily R, Stepanova V, Bobik A, Tkachuk V. Urokinase plasminogen activator enhances intima and media growth and reduces lumen size in carotid arteries. J Hypertension. 2000;18(8):1065-9. doi: 10.1097/00004872-200018080-00011
  13. Plekhanova O, Stepanova V, Ratner E, Bobik A, Tkachuk V, Parfyonova Ye. Urokinase plasminogen activator in injured adventitia increases the number of myofibroblasts and augments early proliferation. J Vasc Res. 2006;43(5):437-46. doi: 10.1159/000094906
  14. Плеханова О.С., Соломатина М.А., Домогатский С.П., Наумов В.Г., Ткачук В.А., Парфенова Е.В., Чазов Е.И. Урокиназа стимулирует, а тканевой активатор плазминогена подавляет развитие стеноза кровеносных сосудов. Российский физиологический журнал им. И.М. Сеченова. 2001;87(5):584-93.
  15. Plekhanova O, Berk B.C, Bashtrykov P, Brooks A, Tkachuk V, Parfyonova Ye. Oligonucleotide microarrays reveal regulated genes related to inward arterial remodeling induced by urokinase plasminogen activator. J Vasc Res. 2009;46(3):177-87. doi: 10.1159/000156703
  16. Plekhanova O, Parfyonova Y, Beloglazova I, Berk B.C and Tkachuk V. Oligonucleotide microarrays identified potential regulatory genes related to early outward arterial remodeling induced by tissue plasminogen activator. Front Physiol. 2019;10:493. doi: 10.3389/fphys.2019.00493
  17. Menshikov M, Plekhanova O, Cai H, Chalupsky K, Parfyonova Y, Bashtrikov P, Tkachuk V, Berk B.C. Urokinase plasminogen activator stimulates vascular smooth muscle cell proliferation via redox - dependent pathways. Arterioscler Thromb Vasc Biol. 2006;26:801-7. doi: 10.1161/0 1.ATV.0000207277.27432.15
  18. Stepanova V, Lebedeva T, Kuo A, Yarovoi S, Tkachuk S, Zaitsev S, Bdeir K, Dumler I, Marks M.S, Parfyonova Y, Tkachuk V.A, Higazi A.A, Cines D.B. Nuclear translocation of urokinase - type plasminogen activator. Blood. 2008;112:100-10. doi: 10.1182/blood-2007-07-104455
  19. Stepanova V, Jayaraman P.S, Zaitsev S.V, Lebedeva T, Bdeir K, Kershaw R, Holman K.R, Parfyonova Y.V, Semina E.V, Beloglazova I.B, Tkachuk V.A, Cines D.B. Urokinase - type plasminogen activator (uPA) promotes angiogenesis by attenuating proline - rich homeodomain protein (PRH) transcription factor activity and de - repressing vascular endothelial growth factor (VEGF) receptor expression. J Biol Chem. 2016;291(29):15029-45. doi: 10.1074/jbc.M115.678490
  20. Van Weel V, van Tongeren R.B, van Hinsbergh V.W, van Bockel J.H, Quax P.H. Vascular growth in ischemic limbs: a review of mechanisms and possible therapeutic stimulation. Ann Vasc Surg. 2008;22:582-97. doi: 10.1016/j.avsg.2008.02.017
  21. Beloglazova I.B, Zubkova E.S, Stambol'skii D.V, Plekhanova O.S, Men'shikov M.Y, Akopyan Zh.A, Bibilashvili R.Sh, Parfenova E.V, Tkachuk V.A. Proteolytically inactive recombinant forms of urokinase suppress migration of endothelial cells. Bull Exp Biol Med. 2014;156(6):756-9. doi: 10.1007/s10517-014-2442-z
  22. Парфенова Е.В., Плеханова О.С., Меньшиков М.Ю., Степанова В.В., Ткачук В.А. Регуляция роста и ремоделирования кровеносных сосудов: уникальная роль урокиназы. Российский физиологический журнал им. И.М. Сеченова. 2009;95(5):442-64.
  23. Traktuev D.O, Tsokolaeva Z.I, Shevelev A.A, Talitskiy K.A, Stepanova V.V, Johnstone B.H, Rahmat-Zade T.M, Kapustin A.N, Tkachuk V.A, March K.L, Parfyonova Y.V. Urokinase gene transfer augments angiogenesis in ischemic skeletal and myocardial muscle. Mol Ther. 2007;15:1939-46. doi: 10.1038/sj.mt.6300262
  24. Semina E, Rubina K, Sysoeva V, Rysenkova K, Klimovich P, Plekhanova O, Tkachuk V. Urokinase and urokinase receptor participate in regulation of neuronal migration, axon growth and branching. Eur J Cell Biol. 2016 Sep;95(9):295-310. doi: 10.1016/j.ejcb.2016.05.003
  25. Семина Е.В., Рубина К.А., Сысоева В.Ю., Макаревич П.И., Парфенова Е.В., Ткачук В.А. Участие урокиназной системы в миграции сосудистых клеток и в регуляции роста и ветвления капилляров. Цитология. 2015;57(10):689-98.
  26. Рубина К.А., Семина Е.В., Ткачук В.А. Навигационные молекулы и хемокины в процессах роста и ремоделирования сосудов. Журнал эволюционной биохимии и физиологии. 2017;5:313-27.
  27. Witmer A.N, van Blijswijk B.C, van Noorden C.J, Vrensen G.F, Schlingemann R.O. In vivo angiogenic phenotype of endothelial cells and pericytes induced by vascular endothelial growth factor-A. J Histochem Cytochem. 2004;52(1):39-52. doi: 10.1177/002215540405200105
  28. Семина Е.В., Рубина К.А., Степанова В.В., Ткачук В.А. Участие рецептора урокиназы и его эндогенных лигандов в развитии головного мозга и формировании когнитивных функций. Российский физиологический журнал им. И.М. Сеченова. 2016;102(8):881-903.
  29. Levitt P. Disruption of Interneuron Development. Epilepsia. 2005; 46(7):22-8. doi: https://doi.org/10.1111/j.1528-1167.2005.00305.x
  30. Semina E.V, Rubina K.A, Stepanova V.V, Tkachuk V.A. Involvement of the Urokinase Receptor and Its Endogenous Ligands in the Development of the Brain and the Formation of Cognitive Functions. Neuroscience and Behavioral Physiology. 2018;48(1):16-27. doi: 10.1007/s11055-017-0525-9
  31. Stone R.C, Pastar I, Ojeh N, Chen V, Liu S, Garzon K.I, Tomic-Canic M. Epithelial - mesenchymal transition in tissue repair and fibrosis. Cell Tissue Res. 2016;365(3):495-506. doi: 10.1007/s00441-016-2464-0
  32. Rybinski B, Franco-Barraza J, Cukierman E. The wound healing, chronic fibrosis, and cancer progression triad. Physiol Genomics. 2014;46(7):223-44. doi: 10.1152/physiolgenomics.00158.2013
  33. Weidenfeld K, Barkan D. EMT and Stemness in Tumor Dormancy and Outgrowth: Are They Intertwined Processes? Front Oncol. 2018;8:381. doi: 10.3389/fonc.2018.00381
  34. Rubina K.A, Sysoeva V.Yu, Zagorujko E.I, Tsokolaeva Z.I, Kurdina M.I, Parfyonova Ye.V, Tkachuk V.A. Increased expression of uPA, uPAR, andPAI-1 in psoriatic skin and in basal cell carcinomas. Archives of Dermatological Research. 2017;309(6):433-42. doi: 10.1007/s00403-017-1738-z
  35. Rysenkova K.D, Semina E.V, Karagyaur M.N, Shmakova A.A, Dyikanov D.T, Vasiluev P.A, Rubtsov Y.P, Rubina K.A, Tkachuk V.A. CRISPR/Cas9 nickase mediated targeting of urokinase receptor gene inhibits neuroblastoma cell proliferation. Oncotarget. 2018;9(50):29414-30. doi: 10.18632/oncotarget.25647
  36. Dyikanov D.T, Vasiluev P.A, Rysenkova K.D, Aleksandrushkina N.A, Tyurin-Kuzmin P.A, Kulebyakin K.Y, Rubtsov Y.P, Shmakova A.A, Evseeva M.N, Balatskiy A.V, Semina E.V, Rostovtseva A.I, Makarevich P.I, Karagyaur M.N. Optimization of CRISPR/Cas9 Technology to Knock Out Genes of Interest in Aneuploid Cell Lines. Tissue Eng Part C Methods. 2019;25(3):168-75. doi: 10.1089/ten.TEC.2018.0365

Copyright (c) 2019 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies